|
1
|
Li D, Xie K, Wolff R and Abbruzzese JL:
Pancreatic cancer. Lancet. 363:1049–1057. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Hidalgo M: Pancreatic cancer. N Engl J
Med. 362:1605–1617. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Berger AC, Garcia M Jr, Hoffman JP, Regine
WF, Abrams RA, Safran H, Konski A, Benson AB III, MacDonald J and
Willett CG: Postresection CA 19–9 predicts overall survival in
patients with pancreatic cancer treated with adjuvant
chemoradiation: A prospective validation by RTOG 9704. J Clin
Oncol. 26:5918–5922. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ferrone CR, Finkelstein DM, Thayer SP,
Muzikansky A, Fernandez-delCastillo C and Warshaw AL: Perioperative
CA19-9 levels can predict stage and survival in patients with
resectable pancreatic adenocarcinoma. J Clin Oncol. 24:2897–2902.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Slidell MB, Chang DC, Cameron JL, Wolfgang
C, Herman JM, Schulick RD, Choti MA and Pawlik TM: Impact of total
lymph node count and lymph node ratio on staging and survival after
pancreatectomy for pancreatic adenocarcinoma: A large,
population-based analysis. Ann Surg Oncol. 15:165–174. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bates GJ, Fox SB, Han C, Leek RD, Garcia
JF, Harris AL and Banham AH: Quantification of regulatory T cells
enables the identification of high-risk breast cancer patients and
those at risk of late relapse. J Clin Oncol. 24:5373–5380. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Cho Y, Miyamoto M, Kato K, Fukunaga A,
Shichinohe T, Kawarada Y, Hida Y, Oshikiri T, Kurokawa T, Suzuoki
M, et al: CD4+ and CD8+ T cells cooperate to
improve prognosis of patients with esophageal squamous cell
carcinoma. Cancer Res. 63:1555–1559. 2003.PubMed/NCBI
|
|
8
|
Clemente CG, Mihm MC Jr, Bufalino R,
Zurrida S, Collini P and Cascinelli N: Prognostic value of tumor
infiltrating lymphocytes in the vertical growth phase of primary
cutaneous melanoma. Cancer. 77:1303–1310. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Fu J, Xu D, Liu Z, Shi M, Zhao P, Fu B,
Zhang Z, Yang H, Zhang H, Zhou C, et al: Increased regulatory T
cells correlate with CD8 T-cell impairment and poor survival in
hepatocellular carcinoma patients. Gastroenterology. 132:2328–2339.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Gao Q, Zhou J, Wang XY, Qiu SJ, Song K,
Huang XW, Sun J, Shi YH, Li BZ, Xiao YS and Fan J: Infiltrating
memory/senescent T cell ratio predicts extrahepatic metastasis of
hepatocellular carcinoma. Ann Surg Oncol. 19:455–466. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kim HI, Kim H, Cho HW, Kim SY, Song KJ,
Hyung WJ, Park CG and Kim CB: The ratio of intra-tumoral regulatory
T cells (Foxp3+)/helper T cells (CD4+) is a prognostic
factor and associated with recurrence pattern in gastric cardia
cancer. J Surg Oncol. 104:728–733. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Pagès F, Berger A, Camus M, Sanchez-Cabo
F, Costes A, Molidor R, Mlecnik B, Kirilovsky A, Nilsson M, Damotte
D, et al: Effector memory T cells, early metastasis and survival in
colorectal cancer. N Engl J Med. 353:2654–2666. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Petersen RP, Campa MJ, Sperlazza J, Conlon
D, Joshi MB, Harpole DH Jr and Patz EF Jr: Tumor infiltrating
Foxp3+ regulatory T-cells are associated with recurrence in
pathologic stage I NSCLC patients. Cancer. 107:2866–2872. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Sinicrope FA, Rego RL, Ansell SM, Knutson
KL, Foster NR and Sargent DJ: Intraepithelial effector
(CD3+)/regulatory (FoxP3+) T-cell ratio
predicts a clinical outcome of human colon carcinoma.
Gastroenterology. 137:1270–1279. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhang L, Conejo-Garcia JR, Katsaros D,
Gimotty PA, Massobrio M, Regnani G, Makrigiannakis A, Gray H,
Schlienger K, Liebman MN, et al: Intratumoral T cells, recurrence,
and survival in epithelial ovarian cancer. N Engl J Med.
348:203–213. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Balch CM, Riley LB, Bae YJ, Salmeron MA,
Platsoucas CD, von Eschenbach A and Itoh K: Patterns of human
tumor-infiltrating lymphocytes in 120 human cancers. Arch Surg.
125:200–205. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Dunn GP, Old LJ and Schreiber RD: The
immunobiology of cancer immunosurveillance and immunoediting.
Immunity. 21:137–148. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Curiel TJ, Coukos G, Zou L, Alvarez X,
Cheng P, Mottram P, Evdemon-Hogan M, Conejo-Garcia JR, Zhang L,
Burow M, et al: Specific recruitment of regulatory T cells in
ovarian carcinoma fosters immune privilege and predicts reduced
survival. Nat Med. 10:942–949. 2004. View
Article : Google Scholar : PubMed/NCBI
|
|
19
|
Hori S, Nomura T and Sakaguchi S: Control
of regulatory T cell development by the transcription factor Foxp3.
Science. 299:1057–1061. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Sakaguchi S, Sakaguchi N, Shimizu J,
Yamazaki S, Sakihama T, Itoh M, Kuniyasu Y, Nomura T, Toda M and
Takahashi T: Immunologic tolerance maintained by CD25+
CD4+ regulatory T cells: Their common role in
controlling autoimmunity, tumor immunity, and transplantation
tolerance. Immunol Rev. 182:18–32. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ademmer K, Ebert M, Muller-Ostermeyer F,
Friess H, Büchler MW, Schubert W and Malfertheiner P: Effector T
lymphocyte subsets in human pancreatic cancer: Detection of
CD8+CD18+ cells and
CD8+CD103+ cells by multi-epitope imaging.
Clin Exp Immunol. 112:21–26. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Gao Q, Qiu SJ, Fan J, Zhou J, Wang XY,
Xiao YS, Xu Y, Li YW and Tang ZY: Intratumoral balance of
regulatory and cytotoxic T cells is associated with prognosis of
hepatocellular carcinoma after resection. J Clin Oncol.
25:2586–2593. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Gooden MJ, de Bock GH, Leffers N, Daemen T
and Nijman HW: The prognostic influence of tumour-infiltrating
lymphocytes in cancer: A systematic review with meta-analysis. Br J
Cancer. 105:93–103. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ikemoto T, Yamaguchi T, Morine Y, Imura S,
Soejima Y, Fujii M, Maekawa Y, Yasutomo K and Shimada M: Clinical
roles of increased populations of Foxp3+CD4+
T cells in peripheral blood from advanced pancreatic cancer
patients. Pancreas. 33:386–390. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Fukunaga A, Miyamoto M, Cho Y, Murakami S,
Kawarada Y, Oshikiri T, Kato K, Kurokawa T, Suzuoki M, Nakakubo Y,
et al: CD8+ tumor-infiltrating lymphocytes together with
CD4+ tumor-infiltrating lymphocytes and dendritic cells
improve the prognosis of patients with pancreatic adenocarcinoma.
Pancreas. 28:e26–e31. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Nukaya I, Yasumoto M, Iwasaki T, Ideno M,
Sette A, Celis E, Takesako K and Kato I: Identification of HLA-A24
epitope peptides of carcinoembryonic antigen which induce
tumor-reactive cytotoxic T lymphocyte. Int J Cancer. 80:92–97.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Duffour MT, Chaux P, Lurquin C, Cornelis
G, Boon T and van der Bruggen P: A MAGE-A4 peptide presented by
HLA-A2 is recognized by cytolytic T lymphocytes. Eur J Immunol.
29:3329–3337. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Bleackley RC: A molecular view of
cytotoxic T lymphocyte induced killing. Biochem Cell Biol.
83:747–751. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Wang RF: The role of MHC class
II-restricted tumor antigens and CD4+ T cells in antitumor
immunity. Trends Immunol. 22:269–276. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Marzo AL, Kinnear BF, Lake RA, Frelinger
JJ, Collins EJ, Robinson BW and Scott B: Tumor-specific
CD4+ T cells have a major ‘post-licensing’ role in CTL
mediated anti-tumor immunity. J Immunol. 165:6047–6055. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Thornton AM and Shevach EM:
CD4+CD25+ immunoregulatory T cells suppress
polyclonal T cell activation in vitro by inhibiting
interleukin 2 production. J Exp Med. 188:287–296. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Sakaguchi S: Naturally arising
CD4+ regulatory t cells for immunologic self-tolerance
and negative control of immune responses. Annu Rev Immunol.
22:531–562. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Hiraoka N, Onozato K, Kosuge T and
Hirohashi S: Prevalence of FOXP3+ regulatory T cells increases
during the progression of pancreatic ductal adenocarcinoma and its
premalignant lesions. Clin Cancer Res. 12:5423–5434. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Wachsmann MB, Pop LM and Vitetta ES:
Pancreatic ductal adenocarcinoma: A review of immunologic aspects.
J Investig Med. 60:643–663. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Ino Y, Yamazaki-Itoh R, Shimada K, Iwasaki
M, Kosuge T, Kanai Y and Hiraoka N: Immune cell infiltration as an
indicator of the immune microenvironment of pancreatic cancer. Br J
Cancer. 108:914–923. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Kobayashi N, Kubota K, Kato S, Watanabe S,
Shimamura T, Kirikoshi H, Saito S, Ueda M, Endo I, Inayama Y, et
al: FOXP3+ regulatory T cells and tumoral indoleamine
2,3-dioxygenase expression predicts the carcinogenesis of
intraductal papillary mucinous neoplasms of the pancreas.
Pancreatology. 10:631–640. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Liyanage UK, Moore TT, Joo HG, Tanaka Y,
Herrmann V, Doherty G, Drebin JA, Strasberg SM, Eberlein TJ,
Goedegebuure PS and Linehan DC: Prevalence of regulatory T cells is
increased in peripheral blood and tumor microenvironment of
patients with pancreas or breast adenocarcinoma. J Immunol.
169:2756–2761. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Oshikiri T, Miyamoto M, Shichinohe T,
Suzuoki M, Hiraoka K, Nakakubo Y, Shinohara T, Itoh T, Kondo S and
Katoh H: Prognostic value of intratumoral CD8+ T
lymphocyte in extrahepatic bile duct carcinoma as essential immune
response. J Surg Oncol. 84:224–228. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Schumacher K, Haensch W, Röefzaad C and
Schlag PM: Prognostic significance of activated CD8(+) T cell
infiltrations within esophageal carcinomas. Cancer Res.
61:3932–3936. 2001.PubMed/NCBI
|
|
40
|
van Beek J, zur Hausen A, Snel SN, Berkhof
J, Kranenbarg EK, van de Velde CJ, van den Brule AJ, Middeldorp JM,
Meijer CJ and Bloemena E: Morphological evidence of an activated
cytotoxic T-cell infiltrate in EBV-positive gastric carcinoma
preventing lymph node metastases. Am J Surg Pathol. 30:59–65. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Grabenbauer GG, Lahmer G, Distel L and
Niedobitek G: Tumor-infiltrating cytotoxic T cells but not
regulatory T cells predict outcome in anal squamous cell carcinoma.
Clin Cancer Res. 12:3355–3360. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Abe M, Kondo S, Hirano S, Ambo Y, Tanaka
E, Morikawa T, Okushiba S and Katoh H: Long-term survival after
radical resection of advanced pancreatic cancer: A case report with
special reference to CD8+ T-cell infiltration. Int J
Gastrointest Cancer. 33:107–110. 2003. View Article : Google Scholar : PubMed/NCBI
|
